Pacific Edge's Cxbladder test incorporated into AUA guideline

Cancer diagnostics company, Pacific Edge, has announced that its Cxbladder Triage test has been incorporated into the American Urological Association's (AUA) clinical guideline for the management of microhematuria.

The AUA's new guideline includes language for the use of urine-based biomarkers in appropriately counseled intermediate-risk patients, specifically mentioning Cxbladder Triage as the only urine biomarker with 'Grade A' evidence.

Intermediate-risk patients are estimated to represent 70% of those presenting with microhematuria.

The guideline states that clinicians may offer urine cytology or validated urine-based tumor markers to facilitate the decision regarding the utility of cystoscopy in these patients.

Pacific Edge anticipates an increase in demand for Cxbladder tests as more clinicians incorporate the updated guideline into their care pathways.

The company also plans to leverage the guideline language in its ongoing policy dialogue with Medicare Administrative Contractor Novitas and the Centers for Medicare and Medicaid Services.